{"filing":{"accession_number":"0001730463-26-000119","cik":"0001730463","ticker":"AUTL","company_name":"Autolus Therapeutics plc","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"autl-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/autl-20260811.htm"},"events":[{"id":26875,"run_id":24443,"accession_number":"0001730463-26-000119","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Autolus Therapeutics disclosed Q2 2026 financial results on August 11, 2026, reporting net product revenue of $45.7 million (up 119% year-over-year), gross margin improvement to 55%, an operating loss of $43.8 million, and a net loss of $39.1 million. The company also provided updated full-year 2026 revenue guidance of $140–$150 million and discussed operational updates including a debt facility and workforce reduction.","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28160,"accession_number":"0001730463-26-000119","item_number":"2.02","item_title":"Results of Operations and Financial Conditions.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026). The filing discloses quarterly financial results including product revenue of $45.7 million (up 119% YoY), cost of sales, gross margin improvement to 55%, operating loss of $43.8 million, and net loss of $39.1 million. The press release also provides updated full-year 2026 revenue guidance ($140–$150 million) and discusses operational updates including a debt facility and workforce reduction. This is material to investors assessing the company's commercial progress and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:34:57.750442+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28161,"accession_number":"0001730463-26-000119","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure explicitly states the company will utilize an updated corporate presentation in connection with its conference call \"to discuss its results for the quarter ended June 30, 2026.\" The supplemental exhibits include a detailed press release (EX-99.1) announcing Q2 2026 financial results, including net product revenue of $45.7 million (119% YoY growth), gross margin improvement to 55%, and updated FY 2026 guidance of $140-$150 million. This is a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:34:57.750442+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28160,"accession_number":"0001730463-26-000119","item_number":"2.02","item_title":"Results of Operations and Financial Conditions.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026). The filing discloses quarterly financial results including product revenue of $45.7 million (up 119% YoY), cost of sales, gross margin improvement to 55%, operating loss of $43.8 million, and net loss of $39.1 million. The press release also provides updated full-year 2026 revenue guidance ($140–$150 million) and discusses operational updates including a debt facility and workforce reduction. This is material to investors assessing the company's commercial progress and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:34:57.750442+00:00","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-11"},{"id":28161,"accession_number":"0001730463-26-000119","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure explicitly states the company will utilize an updated corporate presentation in connection with its conference call \"to discuss its results for the quarter ended June 30, 2026.\" The supplemental exhibits include a detailed press release (EX-99.1) announcing Q2 2026 financial results, including net product revenue of $45.7 million (119% YoY growth), gross margin improvement to 55%, and updated FY 2026 guidance of $140-$150 million. This is a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:34:57.750442+00:00","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-11"}]}